Skip to main content

Primary Immunodeficiency clinical trials at UC Health
1 research study open to new patients

  • A Phase 3, Multinational, Multicenter, Open-Label Study of ProMetic BioTherapeutics IVIG

    open to eligible people ages 2-80

    A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children with Primary Immunodeficiency Diseases (PIDD) to assess the tolerability, safety, efficacy and pharmacokinetics of ProMetic's IGIV in subjects with PIDD. IGIV is intended for the treatment of children and adults with Primary Immunodeficiency Diseases (PIDD) who require IgG (Immunoglobulin G) replacement therapy

    at UC Irvine